Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
0 drugs in development
By Therapeutic Area
top 1
R&D Momentum
61/100
Pipeline Velocity
25/100
Trial Completion Rate
91/100
Pipeline Concentration
100/100
Pipeline Freshness
73/100
Activity
Last 14 days
Randomized Trial Comparing Immediate Versus Deferred Surgery for Symptomatic Epiretinal Membranes
A Randomized Placebo-controlled Trial of Spectacles With Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in Children
A Study of Uveitis in Children <18 Years of Age
A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
Rate of Progression in USH2A-related Retinal Degeneration
Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS)
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Gyrate Atrophy Ocular and Systemic Study
A Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss Due to Radiation Retinopathy
Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)